Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Juneteenth
Donald Trump
G7
Federal Reserve
Social Media
Artificial Intelligence
US Politics
War
Senate
World Cup
Republican Party
US Immigration
Published • loading... • Updated

Looking Ahead to Povorcitininb for HS and the Availability of Generic Tofacitinib

Summary by dermatologytimes.com
At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
dermatologytimes.comdermatologytimes.com

Looking Ahead to Povorcitininb for HS and the Availability of Generic Tofacitinib

At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

dermatologytimes.com broke the news in on Friday, June 13, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Maryland

Maryland

News
For You
SearchBlindspotLocal